Fig. 1
From: Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors
Doxorubicin (an anthracycline, A) disrupts the normal catalytic cycle of topoisomerase 2β, causing deoxyribonucleic acid (DNA) double-stranded breaks. Doxorubicin also changes the transcriptome, leading to defective mitochondrial biogenesis and increasing reactive oxygen species (ROS). As a result, cardiomyocytes show myofibrillar disarray and vacuolization. In the inset, dexrazoxane binds to topoisomerase 2β to prevent anthracycline binding. Produced by permission from Vejpongsa P, Yeh ETH. J Am Coll Cardiol 2014;64:938–45